Key points from article :
New company Vandria develops drugs for ageing and chronic diseases.
They focus on a process called mitophagy, where damaged parts of cells are cleaned up.
First drug, VNA-318, targets brain diseases like Alzheimer's and Parkinson's and tests in animals show it improves memory and protects brain cells.
Clinical trials for VNA-318 starting in Europe in 2024 which will test the drug in people for the first time.
$20.6 million funding from ND Capital and others will help Vandria develop VNA-318 further and explore other drugs based on mitophagy.
The global market for Alzheimer's drugs alone is expected to reach $7.6 billion by 2035.
